Fujian Haixi Pharmaceuticals Co., Ltd. (hereinafter referred to as "Haixi Pharma") was established in Fuzhou in March 2012 with the strong support from both the Fujian provincial and Fuzhou municipal governments and relevant authorities. Haixi Pharma is a pharmaceutical enterprise built around the Marketing Authorization Holder (MAH) system, covering the entire industry value chain from R&D, clinical research, and manufacturing to commercialization.
Over the past course 13 years, Haixi Pharma has taken an extraordinary development path – pursuing a dua strategy of generics and innovative drugs, adhering to the principle of "generics empower innovation, innovation drives the future".
In generics, the company focuses on the research and development of first-to-market generics, difficult-to-formulate generics, and high-value-generics. By leveraging favorable national pharmaceutical policies—such as the MAH system, generic drugs consistency evaluation, and the national centralized drug procurement-Haixi Pharma has achieved remarkable results. As of October 2025, 13 drugs have been approved for marketing and sale by the National Medical Products Administration (NMPA). Among them, Mosapride Citrate Tablets (Ambili ?), Sinacaraside Hydrochloride Tablets (Ruantuo ?), and Amlodipine atorvastatin Calcium Tablets (Haihuitong ?) successfully won the bids in the 4th, 5th, 8th, and 10th rounds of national centralized drug procurement, gaining the market access across 10, 7, 9 and 6 provinces, respectively. These achievements in generics have not only ensured the company’s steady growth but also provided strong momentum for innovation.
In innovative drugs, Haixi Pharma focuses on developing small-molecule drugs with clear medical need and global market potential. Its lead program, C019199, is about to enter Phase III clinical trials, marking a new stage in the company’s innovation pipeline.
Haixi’s R&D team is led by Dr. Xinshan Kang, a National Overseas High-level Entrepreneurial Talent, and brings together a group of PhDs and Masters, including National and Provincial Overseas High-level Entrepreneurial and Scientific Talents as well as "Double Hundred Talent Program" awardees.
The company actively promotes academia–industry collaborations, serving as an internship base for many universities such as Fuzhou University, Fujian Medical University, and Minjiang University, while also carrying out joint research projects with institutions such as Peking University and Xiamen University.
Over the past 13 years, Haixi Pharma has received numerous honors as the results of its relentless efforts in the pharmaceutical field. This includes National High-Tech enterprises, National "Little Giant" Enterprises, among the first batch of Provincial New R&D Institutions in Fujian Province, Fujian Province Science and Technology enterprises, Fujian Province Science and Technology Small Giant Enterprises, Key Pre-IPO Enterprises in Fujian Province and Fuzhou City, the first company in Fujian Province to obtain a Category B "Drug Manufacturing License" (B Certificate), and Fuzhou Municipal Enterprise Technology Centers. As of October 2025, Haixi Pharma has been granted more than 30 invention patents.
Looking ahead, Haixi will continue to uphold its corporate spirit of "result-oriented and hard work", adhere to its core values of "innovation, integrity, sharing and goodwill." With both a down-to-earth approach and visionary ambition, the company will keep expanding its portfolio of globally competitive innovative medicines, striving to realize its vision: “Best Medicine Made Available to People.”
Fujian Haixi New Pharmaceutical Creation Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min) - Non-operating-2023-0063
Some of the text and pictures on this site are from the Internet and are only used for sharing and learning. If your rights and interests are infringed, please inform us in time, and this site will deal with or replace them in time.
